A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093 on ClinicalTrials.gov · last registry update 2026-07-23
Closed to new participants; the 586 already enrolled are still being followed. Due to report September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Pain Intensity Per Numeric Rating Scale. Sponsors move these dates routinely; any movement since this site started watching is listed below. retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- retatrutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 586
- Started
- 2025-05-29
- Primary completion
- 2027-09 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Pain Intensity Per Numeric Rating Scale
Conditions studied
Obesity · Overweight · Chronic Low Back Pain (CLBP)
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.